View More Recent Stories
-
Monopar Therapeutics (MNPR) Reports Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
-
Monopar Therapeutics (MNPR) Regains Compliance with Nasdaq Minimum Bid Price Rule
-
Monopar Therapeutics (MNPR) Cleared to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
-
Monopar Therapeutics (MNPR) PT Raised to $6 at H.C. Wainwright
-
Monopar Therapeutics (MNPR) Announces 1-for-5 Reverse Stock Split
-
Jones Trading Assumes Monopar Therapeutics (MNPR) at Buy
-
Monopar (MNPR) and NorthStar Amend & Extend Collaboration
